Gyre Therapeutics, Inc. (GYRE) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Gyre Therapeutics, Inc. (GYRE) trades at $7.15 with AI Score 33/100 (Grade D). Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing anti-inflammatory and anti-fibrotic drugs. Market cap: $797M, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: May 9, 2026Analyst Coverage for GYRE: GYRE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GYRE against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GYRE: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Gyre Therapeutics, Inc. (GYRE) Healthcare & Pipeline Overview
Gyre Therapeutics, Inc. develops and commercializes anti-inflammatory and anti-fibrotic drugs, with its lead product ETUARY (Pirfenidone) approved for idiopathic pulmonary fibrosis. The company focuses on addressing organ fibrosis and has multiple Phase 3 trials underway, positioning it within the competitive biotechnology landscape.
What Is the Investment Thesis for GYRE?
Gyre Therapeutics presents a focused investment opportunity within the biotechnology sector, driven by its lead product ETUARY and its pipeline of anti-fibrotic drugs. The ongoing Phase 3 trials for ETUARY in multiple indications, including dermatomyositis and diabetic kidney disease, represent significant potential catalysts for revenue growth. The development of F351 (Hydronidone) targeting chronic hepatitis B liver fibrosis and NASH also offers substantial upside. However, the company's negative profit margin of -5.4% and high beta of 6.40 indicate significant risk and volatility. Successful trial outcomes and regulatory approvals are critical for realizing the company's value. Investors should closely monitor clinical trial data and competitive developments.
Based on FMP financials and quantitative analysis
GYRE Key Highlights
Market capitalization of $797M reflects investor valuation of Gyre's pipeline and approved product.
- Gross margin of 95.1% indicates strong pricing power for ETUARY.
- Profit margin of -5.4% highlights the company's current reliance on R&D investments and clinical trial expenses.
- ETUARY (Pirfenidone) is approved for idiopathic pulmonary fibrosis, providing a stable revenue stream.
- Multiple Phase 3 trials underway for ETUARY and F351 targeting various fibrotic diseases, offering potential for significant market expansion.
Who Are GYRE's Competitors?
GYRE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ERAS Erasca, Inc. | $18.07 | -0.17% | $6.27B | 66 |
| GNFTF Genfit S.A. | $16.50 | +3.45% | $827M | 73 |
| RIGL Rigel Pharmaceuticals, Inc. | $45.09 | -3.97% | $834M | 84 |
| TBPH Theravance Biopharma, Inc. | $16.99 | +0.24% | $881M | 95 |
| ZVRA Zevra Therapeutics, Inc. | $12.13 | +4.84% | $717M | 93 |
| ALBO Albireo Pharma, Inc. | $44.15 | +0.00% | $916M | 71 |
| CRMD CorMedix Inc. | $8.33 | -2.19% | $654M | 95 |
| MDXG MiMedx Group, Inc. | $4.45 | +2.53% | $649M | 90 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GYRE's Key Strengths?
Approved product (ETUARY) for idiopathic pulmonary fibrosis.
- Multiple Phase 3 trials underway for ETUARY and F351.
- Strong gross margin of 95.1%.
- Experienced management team with expertise in drug development.
What Are GYRE's Weaknesses?
Negative profit margin of -5.4%.
- High beta of 6.40 indicates significant volatility.
- Reliance on successful clinical trial outcomes and regulatory approvals.
- Competition from other pharmaceutical companies developing therapies for fibrotic diseases.
What Could Drive GYRE Stock Higher?
GYRE catalyst: Completion of Phase 3 trials for ETUARY in dermatomyositis, systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease.
- Completion of Phase 3 trials for F351 in chronic hepatitis B liver fibrosis.
- Advancement of F573 into later-stage clinical trials for acute/acute-on-chronic liver failure.
- Preclinical development of F528 for COPD and F230 for pulmonary arterial hypertension.
What Are the Key Risks for GYRE?
Negative return on equity (-6.3%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for pipeline assets.
- Competition from biosimilars and generic versions of ETUARY.
- Adverse clinical trial results.
- Changes in regulatory landscape and reimbursement policies.
- High beta of 6.40 indicates significant market volatility.
What Are the Growth Opportunities for GYRE?
- Expansion of ETUARY into new indications: ETUARY is currently in Phase 3 trials for dermatomyositis, systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. Successful completion of these trials and subsequent regulatory approvals could significantly expand the market for ETUARY, potentially adding hundreds of millions of dollars in revenue. The market for diabetic kidney disease therapeutics alone is projected to reach $2.9 billion by 2028.
- Development of F351 for chronic hepatitis B liver fibrosis and NASH: F351 (Hydronidone) is a structural derivative of Pirfenidone that is being developed for the treatment of chronic hepatitis B liver fibrosis and NASH. NASH is a rapidly growing market with limited treatment options, and successful development of F351 could provide a significant growth opportunity for Gyre Therapeutics. The NASH market is projected to reach $25 billion by 2030.
- Advancement of F573 for acute/acute-on-chronic liver failure: F573 is currently in Phase 2 studies for the treatment of acute/acute-on-chronic liver failure. This is a critical unmet medical need, and successful development of F573 could provide a valuable treatment option for patients with this condition. The market for liver failure therapeutics is projected to reach $1.5 billion by 2027.
- Preclinical development of F528 for COPD: F528 is in preclinical development for the treatment of chronic obstructive pulmonary disease (COPD). COPD is a major cause of morbidity and mortality worldwide, and new treatments are needed to improve patient outcomes. Successful development of F528 could provide a significant growth opportunity for Gyre Therapeutics. The COPD market is projected to reach $16.8 billion by 2028.
- Preclinical development of F230 for pulmonary arterial hypertension: F230 is in preclinical development for the treatment of pulmonary arterial hypertension (PAH). PAH is a rare but serious condition that affects the arteries in the lungs. New treatments are needed to improve the quality of life and survival of patients with PAH. The PAH market is projected to reach $7.2 billion by 2027.
What Are GYRE's Competitive Advantages?
- Patent protection for ETUARY (Pirfenidone) and other pipeline assets.
- Established manufacturing and distribution infrastructure for ETUARY.
- Clinical data and regulatory approvals for ETUARY in IPF.
- Expertise in the development of anti-fibrotic drugs.
What Does GYRE Do?
Founded in 2002 and headquartered in San Diego, California, Gyre Therapeutics, Inc. is a pharmaceutical company specializing in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company's lead product, ETUARY (Pirfenidone), is an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis (IPF). ETUARY is also undergoing Phase 3 studies for various other fibrotic conditions, including dermatomyositis, systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. Gyre Therapeutics is also developing F351 (Hydronidone), a structural derivative of Pirfenidone, which is currently in Phase 3 studies for chronic hepatitis B liver fibrosis and Phase 1 studies for liver fibrosis associated with nonalcoholic steatohepatitis (NASH). The company's pipeline also includes F573 in Phase 2 for acute/acute-on-chronic liver failure, F528 in preclinical development for chronic obstructive pulmonary disease (COPD), and F230 in preclinical development for pulmonary arterial hypertension. Gyre Therapeutics operates as a subsidiary of GNI USA, Inc.
What Products and Services Does GYRE Offer?
- Develop and commercialize small-molecule, anti-inflammatory, and anti-fibrotic drugs.
- Offer ETUARY (Pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF).
- Conduct Phase 3 studies for ETUARY in dermatomyositis, systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease.
- Develop F351 (Hydronidone) for chronic hepatitis B liver fibrosis and NASH.
- Advance F573 for the treatment of acute/acute-on-chronic liver failure.
- Conduct preclinical research on F528 for chronic obstructive pulmonary disease (COPD).
- Conduct preclinical research on F230 for pulmonary arterial hypertension (PAH).
How Does GYRE Make Money?
- Develop and commercialize proprietary pharmaceutical products.
- Generate revenue through the sale of ETUARY (Pirfenidone).
- Out-license or partner for the development and commercialization of pipeline assets.
- Secure funding through equity financing, debt financing, and government grants.
What Industry Does GYRE Operate In?
Gyre Therapeutics operates within the biotechnology industry, which is characterized by high R&D spending, lengthy regulatory approval processes, and intense competition. The market for anti-fibrotic drugs is growing due to the increasing prevalence of chronic diseases such as idiopathic pulmonary fibrosis, liver fibrosis, and kidney disease. Key trends include the development of novel small-molecule therapies and the use of biomarkers to identify patients who are most likely to respond to treatment. Gyre Therapeutics competes with other pharmaceutical companies developing therapies for fibrotic diseases, including ERAS: Erasca, Inc.
Who Are GYRE's Key Customers?
- Patients with idiopathic pulmonary fibrosis (IPF).
- Patients with dermatomyositis, systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease (if ETUARY is approved for these indications).
- Patients with chronic hepatitis B liver fibrosis and NASH (if F351 is approved).
- Hospitals, clinics, and pharmacies that purchase and dispense Gyre Therapeutics' products.
Forward Outlook
Wall Street analysts project Gyre Therapeutics, Inc. revenue of about $102.3M for fiscal 2026, with EPS near $-0.29.
Quarterly Financial Performance: Gyre Therapeutics, Inc.
Revenue for Gyre Therapeutics, Inc. came in at $29.1M during Q2 2026, a 29.2% improvement versus the preceding quarter. The company recorded a net loss of $10.6M, with diluted EPS of $-0.12. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, GYRE averaged $-0.05 in diluted EPS.
GYRE Valuation & Market Position
With a $797M market cap, Gyre Therapeutics, Inc. sits in the small-cap segment of the market. Relative to its peer group, GYRE's quantitative score of 33/100 is below the peer average of 82/100.
Key Financial Metrics
Return on equity for Gyre Therapeutics, Inc. stands at -6.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -3.9%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.64 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Gyre Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 13.52 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
Gyre Therapeutics, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 28.3% below estimates on average.
Company Profile
Gyre Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Ying Luo. GYRE has traded publicly since 2006.
GYRE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Gyre's future, indicating that leadership believes in the company's potential.
- Community sentiment has shifted positively, with discussions around recent advancements in their therapeutic pipeline gaining traction.
- Positive media coverage highlighting Gyre's innovative approach has sparked interest among retail investors, boosting overall sentiment.
- The company's strategic partnerships are seen as a strong indicator of future growth, enhancing credibility in the biotech space.
Bear Case
- Concerns about the competitive landscape in the biotech sector have emerged, with several competing therapies gaining attention.
- Recent clinical trial results have raised questions, leading to skepticism about the efficacy of Gyre's offerings among investors.
- Social sentiment has shown some volatility, with bearish discussions increasing due to perceived delays in product development timelines.
- Market perception is cautious, as investors weigh the risks associated with regulatory approvals and the lengthy nature of biotech advancements.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $29M | -$11M | -$0.12 |
| Q1 2026 | $23M | -$9M | -$0.10 |
| Q4 2025 | $37M | -$2M | -$0.02 |
| Q3 2025 | $31M | $4M | $0.03 |
Based on FMP financials and quantitative analysis
GYRE Latest News
-
Earnings Scheduled For March 12, 2026
benzinga · Mar 12, 2026
GYRE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GYRE.
Price Targets
Wall Street price target analysis for GYRE.
GYRE MoonshotScore
What does this score mean?
The MoonshotScore rates GYRE 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Ping Zhang
CEO
Ping Zhang is the CEO of Gyre Therapeutics, Inc. He has extensive experience in the pharmaceutical industry, with a focus on drug development and commercialization. Prior to joining Gyre Therapeutics, he held leadership positions at several other pharmaceutical companies, where he was responsible for overseeing the development and launch of multiple products. He holds a Ph.D. in Pharmaceutical Sciences and has published numerous articles in peer-reviewed journals.
Track Record: Under Ping Zhang's leadership, Gyre Therapeutics has made significant progress in advancing its pipeline of anti-fibrotic drugs. Key achievements include the successful approval of ETUARY (Pirfenidone) for idiopathic pulmonary fibrosis and the initiation of Phase 3 trials for ETUARY in multiple new indications. He has also overseen the development of F351 (Hydronidone) and its advancement into Phase 3 clinical trials.
What Investors Ask About Gyre Therapeutics, Inc. (GYRE) — Healthcare
What does the AI Score mean for GYRE?
GYRE holds an AI Score of 33/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing anti-inflammatory and anti-fibrotic drugs. Their lead product, ETUARY (Pirfenidone), is approved …
What does Gyre Therapeutics, Inc. do?
Gyre Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of drugs targeting organ fibrosis. Its primary product, ETUARY (Pirfenidone), is approved for treating idiopathic pulmonary fibrosis (IPF). The company is also actively involved in clinical trials, particularly Phase 3 studies, to expand the use of ETUARY for other fibrotic conditions like dermatomyositis and diabetic kidney disease.
What do analysts say about GYRE stock?
Analyst coverage of Gyre Therapeutics is focused on the potential of its pipeline and the market opportunity for ETUARY. Key valuation metrics include projected peak sales for ETUARY in various indications and the potential for F351 to address the growing NASH market.
What are the main risks for GYRE?
Gyre Therapeutics faces several key risks, including the potential for clinical trial failures, regulatory hurdles, and competition from other pharmaceutical companies. The company's reliance on ETUARY and its pipeline assets means that any setbacks in clinical development or regulatory approval could significantly impact its financial performance.
How does Gyre Therapeutics, Inc. navigate regulatory approval processes?
Gyre Therapeutics navigates regulatory approval processes primarily through rigorous clinical trials designed to meet the standards of regulatory bodies like the FDA. The company's strategy involves conducting comprehensive Phase 3 trials for its lead drug, ETUARY, across multiple indications, ensuring robust data collection and analysis.
How does Gyre Therapeutics, Inc. manage patent expiration risks?
Gyre Therapeutics manages patent expiration risks through a multi-faceted approach that includes extending patent protection through formulation and indication expansions, as well as developing new chemical entities with their own patent life cycles. For ETUARY, the company seeks to secure additional patents for new uses and formulations to prolong its market exclusivity.
What are the key factors to evaluate for GYRE?
Gyre Therapeutics, Inc. (GYRE) holds an AI score of 33/100 (low). P/E: 129.1x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does GYRE data refresh on this page?
GYRE's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven GYRE's recent stock price performance?
Gyre Therapeutics, Inc. (GYRE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Approved product (ETUARY) for idiopathic pulmonary fibrosis. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-05-09.
- Financial data may be subject to change.